UTL-5g

Research use only, not for human use.

UTL-5g is a novel potential chemoprotective agent, TNF-α inhibitor that reduces cisplatin-induced side effects including nephrotoxicity, hepatotoxicity and hematotoxicity.

UTL-5g is a novel potential chemoprotective agent, TNF-α inhibitor that reduces cisplatin-induced side effects including nephrotoxicity, hepatotoxicity and hematotoxicity. It lowers elevated levels of AST, ALT, creatinine, BUN, and TNF-α, increases the reduced platelet count in mice, and acts as a novel chemo- and radioprotective agent.

RAW 264.7 macrophages are transfected with the respective reporter assay plasmids, pretreated with UTL-5g at 1, 10 or 50 μM for 60 min and then challenged with 100 ng/ml LPS. After a 16 h incubation, transcription factor activity is measured. Transcription factors that shows a UTL-5g dose-dependent decrease in activity in two experiments are categorized as being disrupted by UTL-5g.

UTL-5g (GBL-5g) lowers levels of TGF-β and TNF-α elevated by lung irradiation.UTL-5g (60 mg/kg; p.o.; daily for 4 days) shows positive effects in increasing the survival rates and extending the survival times. Animal Model:C57BL/6, male mice (8-10 weeks)Dosage:15, 30, and 60 mg/kg Administration:I.p.; before irradiation, daily x 5Result:Blood levels of TGF-β were lowered.Animal Model:BDF1 female mice Dosage:P.o.; daily for 4 days Administration:60 mg/kg (30 min before i.p. injection of Cisplatin at 10, 15, and 20 mg/kg respectively on Day 0)Result:Increased the survival rate and delayed the time to death for mice treated with 150% of the maximum tolerated dose (MTD) of Cisplatin (15 mg/kg). At 200% of the MTD of Cisplatin (20 mg/kg), treatment of UTL-5g increased the survival rate and delayed the time to death.

3-Isoxazolecarboxamide, N-(2,4-dichlorophenyl)-5-methyl- | GBL-5g

Apoptosis

TNF

TNF-α

——

——

646530-37-2

271.1

C11H8Cl2N2O2

>98% (HPLC)

DMSO:10 mM

O=C(C1=NOC(C)=C1)NC2=CC=C(Cl)C=C2Cl

——

(-20℃)

With Ice Pack

≥ 2 years